Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
The Alexander Mosley Charitable Trust and by the founding partners of Imperial College London's Centre for Psychedelic Research.
Authors
- Tommaso Barba (ORCID: https://orcid.org/0000-0003-2565-4628)
- Brandon Weiss (ORCID: https://orcid.org/0000-0003-2989-2981)
- Ashleigh Murphy-Beiner
- Jonny Martell (ORCID: https://orcid.org/0000-0002-4194-7669)
- Robin Lester Carhart-Harris (ORCID: https://orcid.org/0000-0002-6062-7150)
- David Erritzøe (ORCID: https://orcid.org/0000-0002-7022-6211)
- Christopher Timmermann (ORCID: https://orcid.org/0000-0002-2281-377X)
- Bruna Giribaldi
- Kyle T. Greenway (ORCID: https://orcid.org/0000-0002-7829-493X)
- Roberta Murphy
- Michelle Baker Jones
- David Nutt
Institutions
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- Imperial College London (GB)
- McGill University (CA)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1016/j.eclinm.2024.102799
- Citations
- 37
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 23.64
Funders
- National Institute for Health and Care Research
- Imperial College London
- NIHR Imperial Biomedical Research Centre